EUVIMEDEUVIMED entdecken
Open Access

Circulating Factors in Single Ventricle Heart Disease Impair Cardiomyocyte Bioenergetics, With Partial Rescue by PDE5 Inhibition

Anastacia M Garcia iD, Ashley E Pietra iD, Mary E Turner iD, Julie Pires Da Silva iD, Angela Baybayon-Grandgeorge, Genevieve C Sparagna iD, Danielle A Jeffrey iD, Brian L Stauffer iD, Carmen C Sucharov iD, Shelley D Miyamoto iD

Journal of the American Heart Association · 01.09.2026 · 15 (17)

DOI: 10.1161/jaha.125.042725 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 01.09.2026. Verfasst von Anastacia M Garcia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiology, Department of Pediatrics University of Colorado Anschutz Medical Campus, Children's Hospital Colorado Aurora CO USA. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Energy Metabolism, Phosphodiesterase 5 Inhibitors, Mitochondria, Heart. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although operative and perioperative care continues to improve for patients with single ventricle (SV) congenital heart disease, long‐term morbidities and mortality remain high. Importantly, phosphodiesterase‐5 inhibitor (PDE5i) therapies are increasingly used, but their direct myocardial effects in SV congenital heart disease remain poorly understood. We previously demonstrated that the failing SV myocardium is characterized by increased PDE5 (phosphodiesterase‐5) activity and impaired mitochondrial bioenergetics. Here we sought to determine whether systemic circulating factors contribute to pathological metabolic remodeling in SV congenital heart disease, and whether PDE5i therapy mitigates these changes.

Methods

Using an established in vitro model whereby primary cardiomyocytes are treated with patient sera ± PDE5i, we assessed the impact of circulating factors on cardiomyocyte metabolism. Mass spectrometry‐based lipidomics and metabolomics assessed phospholipid and metabolite changes. Mitochondrial bioenergetics were evaluated using the Seahorse Bioanalyzer and a stable isotope‐based enzyme activity assay. Relative mitochondrial copy number was quantified using reverse transcriptase–quantitative polymerase chain reaction.

Results

Our data suggest that circulating factors contribute to fundamental changes in cardiomyocyte bioenergetics, including impaired mitochondrial function associated with decreased cardiolipin and other phospholipid species, impaired carnitine palmitoyltransferase activity, increased reactive oxygen species generation, and altered metabolite milieu. PDE5i treatment partially reversed these abnormalities by restoring phosphatidylglycerol levels, reducing reactive oxygen species, increasing carnitine palmitoyltransferase activity, improving energy production, and normalizing several metabolic intermediates.

Conclusions

Together, these data suggest circulating factors directly impair cardiomyocyte mitochondrial bioenergetics and may drive systemic metabolic dysfunction in SV congenital heart disease. PDE5i therapy partially attenuates these effects, supporting metabolic modulation as a potential therapeutic strategy for SV failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacEnergy MetabolismPhosphodiesterase 5 InhibitorsMitochondria, HeartUniventricular HeartHumansCells, CulturedMaleAnimalsMetabolomics

Stichwörter der Autor:innen

bioenergeticscongenital heart diseasehypoplastic left heart syndromemetabolismmitochondriaphosphodiesterase‐5single ventricle

Substanzen

Phosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Section of Cardiology, Department of Pediatrics University of Colorado Anschutz Medical Campus, Children's Hospital Colorado Aurora CO USA.
  • Division of Cardiology, Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO USA.
  • Division of Cardiology Denver Health Medical Center Denver CO USA.

ORCID-Profile: Anastacia M Garcia, Ashley E Pietra, Mary E Turner, Julie Pires Da Silva, Genevieve C Sparagna, Danielle A Jeffrey, Brian L Stauffer, Carmen C Sucharov, Shelley D Miyamoto

Zitieren

APA

Garcia, A. M., Pietra, A. E., Turner, M. E., Da Silva, J. P., Baybayon-Grandgeorge, A., Sparagna, G. C., Jeffrey, D. A., Stauffer, B. L., Sucharov, C. C., & Miyamoto, S. D. (2026). Circulating Factors in Single Ventricle Heart Disease Impair Cardiomyocyte Bioenergetics, With Partial Rescue by PDE5 Inhibition. Journal of the American Heart Association, 15(17). https://doi.org/10.1161/jaha.125.042725

Vancouver

Garcia AM, Pietra AE, Turner ME, Da Silva JP, Baybayon-Grandgeorge A, Sparagna GC, et al. Circulating Factors in Single Ventricle Heart Disease Impair Cardiomyocyte Bioenergetics, With Partial Rescue by PDE5 Inhibition. Journal of the American Heart Association. 2026;15(17). doi:10.1161/jaha.125.042725

BibTeX
@article{Garcia2026,
  author = {Garcia, Anastacia M and Pietra, Ashley E and Turner, Mary E and Da Silva, Julie Pires and Baybayon-Grandgeorge, Angela and Sparagna, Genevieve C and Jeffrey, Danielle A and Stauffer, Brian L and Sucharov, Carmen C and Miyamoto, Shelley D},
  title = {Circulating Factors in Single Ventricle Heart Disease Impair Cardiomyocyte Bioenergetics, With Partial Rescue by PDE5 Inhibition},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {17},
  doi = {10.1161/jaha.125.042725}
}
Kostenlos starten →